Tempus AI reported third-quarter revenue of $411.5 million, a 23% increase year-over-year, driven by 32% growth in oncology volume and 33% growth in Data & Applications. The company posted an adjusted EBITDA of $25.6 million compared to $1.5 million in the prior year period. Tempus raised its full-year 2026 revenue guidance to $1.60–$1.605 billion and expects adjusted EBITDA of approximately $65 million. The firm also announced a strategic collaboration with Merck and Moderna for neoantigen therapy commercialization and received FDA clearances for two AI cardiology products. Tempus is a technology company applying artificial intelligence to advance precision medicine through diagnostics, data analytics, and clinical workflows.
